Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Minnesota Board Won’t Set Rules on Execution Drugs

By Drug Discovery Trends Editor | December 11, 2014

Minnesota pharmacy regulators declined Wednesday to set a pioneering policy sought by death-penalty opponents that would explicitly bar the manufacture of lethal drugs for use in executions elsewhere.

The state Board of Pharmacy put the request aside without voting on it. Its leaders said they saw little need to be dragged into an emotional debate when they weren’t aware of any cases in which Minnesota pharmacists supplied execution drugs. They say that possibility is remote and likely would run afoul of existing law.

“We haven’t had the death penalty in Minnesota in 100 years,” said board president Stuart Williams. “This is not an issue that is confronting any of the pharmacies or pharmacists in Minnesota.”

A coalition of advocacy groups seeking the formal policy chose Minnesota – and will head next to other no-execution states like Wisconsin – because they are looking for a sympathetic launching pad for a restriction they hope will catch on. Their goal is to deny capital punishment states vital ingredients for putting condemned inmates to death.

Several drugmakers, including many abroad, have stopped selling drugs common in lethal injection. So death-penalty states have turned to compounding pharmacies for substitutes. Some won’t disclose where they get the drugs, leaving open the possibility that they’re coming from other states.

National associations for doctors and anesthesiologists have codes of ethics restricting credentialed members from carrying out executions. The national association for pharmacists hasn’t adopted one, stirring the state-level campaigning.

Rosalyn Park, research director at The Advocates for Human Rights, recounted recent executions that had problems as she urged the Minnesota regulators to be trailblazers.

“This is tantamount to torture and pharmacists should in no way have to be put into that position of having to make, sell or otherwise provide these drugs for purposes of such an execution,” Park said.

No one testified against the proposal, though Dudley Sharp of Texas, a defender of the death penalty, wrote to the board in opposition.

“No one believes that the state execution of murderers is a medical procedure between doctor and patient, regardless of the method of execution,” Sharp wrote.

Even without a new policy, it would be difficult for Minnesota pharmacists to produce lethal injection drugs without putting their professional licenses in peril.

Cody Wiberg, the pharmacy board’s executive director, said strict protocols surround compound pharmacies, which are distinct from neighborhood drug stores. For one, state law would demand a specific prescription for a specific inmate that would also require an in-patient physician examination for it to be valid.

“When I take a look at the totality of laws and rules in this state, I think it would be incredibly difficult for a pharmacist to legally participate in this process and not violate one of the rules and statutes involved,” Wiberg said.

Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Recursion Pharmaceuticals Logo
Recursion’s Phase 3 FAP trial will count large-polyp removals as events under FDA-agreed design
Ball-and-stick model of the cancer drug imatinib
After six years in stealth, Humanitas bets on hybrid AI for drug discovery
NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE